A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

This is a phase III, randomized, open-label, multicenter, global study to determine the
efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy
(EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line
treatment in patients with extensive-stage small-cell lung cancer